Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?

Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology 2023 Annual Meeting.

In the study, patients in the OPTIC extension trial continue to experience long-term ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner